These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29344387)

  • 1. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
    Furie RA; Mitrane M; Zhao E; Becker PM
    Lupus Sci Med; 2017; 4(1):e000240. PubMed ID: 29344387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
    Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
    Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
    Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
    van Vollenhoven RF; Stohl W; Furie RA; Fox NL; Groark JG; Bass D; Kurtinecz M; Pobiner BF; Eastman WJ; Gonzalez-Rivera T; Gordon D
    Lupus Sci Med; 2018; 5(1):e000288. PubMed ID: 30588323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
    Askanase AD; Furie RA
    Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
    Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
    Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
    Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
    Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R; Petri MA; Strand V; Gladman DD; Zhong ZJ; Freimuth WW;
    Lupus Sci Med; 2014; 1(1):e000031. PubMed ID: 25396065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
    Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio M; Karlsson D; Furst DE
    Rheumatol Ther; 2022 Apr; 9(2):649-661. PubMed ID: 35184268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Fei K; Gordon RM; Gregan I; Lo KH; Chevrier M; Rose S
    Arthritis Rheumatol; 2020 May; 72(5):761-768. PubMed ID: 31769212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
    Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
    Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
    Wallace DJ; Gordon C; Strand V; Hobbs K; Petri M; Kalunian K; Houssiau F; Tak PP; Isenberg DA; Kelley L; Kilgallen B; Barry AN; Wegener WA; Goldenberg DM
    Rheumatology (Oxford); 2013 Jul; 52(7):1313-22. PubMed ID: 23542611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.